Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-450 open-label extension in cervical dystonia
NCT04871451Phase 2Completed
- Sponsor
- AEON Biopharma, Inc.
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in cervical dystonia (CD), sponsored by AEON Biopharma, Inc. Primary endpoint: Number of Participants With Treatment-related Serious Adverse Events up to 52 weeks. Started Jul 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT04871451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871451.